三、请说明公司及下属公司开发及运营APP、小程序、公众号等产品情况，是否涉及收集和使用个人信 息，如有，请说明收集及储存的用户信息规模、数据收集使用情况。 智通财经APP获悉，10月24日，中国证监会公布《境外发行上市备案补充材料要求(2025年10月20日— 2025年10月24日)》。中国证监会国际司共对11家企业出具补充材料要求，其中，要求宜品集团补充说 明公司实施员工持股计划价格公允性等事项。据悉，宜品集团已于2025年8月31日向港交所主板提交上 市申请，海通国际和中信建投国际为联席保荐人。 中国证监会请宜品集团补充说明以下事项，请律师核查并出具明确的法律意见： 一、关于历史沿革：(1)请说明公司2023年2月增资，青岛中旺投资中心(有限合伙)实缴出资情况，以及 2024年12月青岛中旺投资中心(有限合伙)减资的原因以及合规性；(2)请就公司设立及历次股权变动是否 合法合规出具明确结论性意见。 二、请说明公司实施员工持股计划价格公允性，退休离职人员是否继续持有激励份额及其合规性。 六、请说明本次拟参与"全流通"股东所持股份是否存在被质押、冻结或其他权利瑕疵的情形。 招股书显示，宜品集团是一家乳制品企 ...

Core Insights - The increasing awareness and acceptance of goat milk powder among consumers, particularly young families, is driving rapid market growth due to its nutritional benefits and better absorption characteristics [1][7] - In 2024, the retail volume of infant formula goat milk powder in China is projected to reach 50,000 tons, a year-on-year increase of 5.93%, accounting for 71.43% of the total goat milk powder retail volume [1][7] - The retail value of infant formula goat milk powder is expected to reach 18.8 billion yuan, with a year-on-year growth of 8.67%, representing 75.20% of the total retail value of goat milk powder [1][7] Industry Overview - Goat milk powder is made from goat and sheep milk, which has fat globule sizes similar to human milk and a protein structure that closely resembles it, making it suitable for infants with sensitive stomachs or allergies to cow's milk [2][3] - The infant formula goat milk powder market is categorized into three stages based on the age of infants: Stage 1 (0-6 months), Stage 2 (6-12 months), and Stage 3 (12-36 months) [3] Market Policies - Recent policies in China, such as the "14th Five-Year Plan for Dairy Industry Competitiveness Enhancement" and various guidelines for rural revitalization and high-quality development, provide a favorable environment for the growth of the infant formula goat milk powder industry [4] Industry Chain - The upstream of the infant formula goat milk powder industry includes milk source (goat and sheep farming), auxiliary materials, production equipment, and packaging materials, with high-quality milk sources being crucial for product quality [5][6] - Major goat milk farming regions in China include Shaanxi, Shandong, and Henan, with some companies establishing their own farms to ensure quality and safety [5] Competitive Landscape - The domestic brands dominate the infant formula goat milk powder market, accounting for over 90% of registered products, with a high market concentration where the top five companies hold a 60.8% market share [6][8] - Companies like Ausnutria and Yipin Nutrition are key players, with Ausnutria being the first infant formula company listed in Hong Kong and having a significant global presence [8][10] Development Trends - The importance of milk sources will continue to rise, with fresh milk becoming the mainstream raw material, and companies adopting short-chain processing techniques to retain natural nutrients [10] - Innovations in formulations will focus on enhancing nutritional elements such as DHA, ARA, and probiotics, while also addressing the needs of infants with allergies through low-allergen and easily digestible products [10][11]

Overview - The demand for high-quality dairy products, particularly goat milk powder, is increasing due to rising national income levels and health awareness. Goat milk powder is favored for its rich nutrition and easy absorption, especially among the aging population and those with lactose intolerance [1][9]. Market Statistics - In 2024, China's goat milk powder retail volume is projected to reach 70,000 tons, representing a year-on-year growth of 6.87%. The retail value is expected to reach 25 billion yuan, with a year-on-year increase of 9.17% [1][9]. Industry Development - The goat milk powder industry has evolved significantly since the establishment of New China, with key milestones including the 2008 melamine food safety incident that boosted goat milk powder's popularity as a safer alternative to cow milk powder. The industry entered a rapid growth phase post-2018 with the implementation of formula registration systems [7][9]. Market Policies - Recent policies such as the "14th Five-Year Plan for Dairy Industry Competitiveness Enhancement" and various guidelines for rural revitalization and high-quality development have created a favorable environment for the growth of the goat milk powder industry [8]. Industry Chain - The goat milk powder industry chain includes upstream sources like goat farming, midstream production processes, and downstream sales channels such as supermarkets and e-commerce platforms. The consumer base is expanding to include infants, the elderly, and pregnant women [8]. Competitive Landscape - Major dairy companies like Yili, Mengniu, and Ausnutria are entering the goat milk powder market, with significant acquisitions and investments. The market concentration is increasing, with the top five companies holding a 55.6% market share in 2024 [11]. Company Profiles - Ausnutria, established in 2003 and listed in Hong Kong, is a leading player in the goat milk powder sector, with a revenue of 3.887 billion yuan and a gross profit of 1.628 billion yuan in the first half of 2025 [11][12]. - Yipin Nutrition Technology Group focuses on providing high-nutrition, easily absorbed goat milk powder for all age groups, reporting a revenue of 806 million yuan in the first half of 2025, with infant formula accounting for 55.57% of sales [13]. Future Trends - The goat milk powder industry is expected to adopt "short-chain processing" techniques and fresh-keeping technologies to retain the natural nutrients of fresh goat milk. The demand for A2 milk sources and high whey protein products is anticipated to grow, emphasizing the importance of quality and scarcity of milk sources as core competitive advantages [14].

Core Viewpoint - Yipin Nutrition Technology (Qingdao) Group Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, focusing on low-allergen dairy products and special medical formula foods, targeting sensitive consumer groups [1][2]. Company Overview - Yipin Nutrition's core products include low-allergen milk products, such as goat milk powder designed for allergic and lactose-intolerant individuals, and specialized medical formula foods commonly used in hospitals [1]. - The company has a long history, tracing back to 1956, and has evolved from a local dairy enterprise to a comprehensive nutrition technology group covering the entire industry chain [1][3]. - Yipin Nutrition has established its own farms in Heilongjiang and Shandong, and its Spanish factory produces one-quarter of the EU's goat whey powder [1][4]. Financial Performance - Yipin Nutrition's revenue for the years 2022, 2023, 2024, and the first half of 2025 was approximately 1.402 billion, 1.614 billion, 1.762 billion, and 806.8 million RMB, respectively [4]. - The company's annual profits during the same period were approximately 227 million, 168 million, 172 million, and 56.688 million RMB [4]. Market Dynamics - The low-allergen dairy and special medical food sectors are experiencing significant growth, driven by rising allergy rates among infants (12.3%) and increasing demand for medical nutrition due to an aging population [2][7]. - The Chinese goat milk powder market is projected to reach a retail scale of 25 billion RMB by 2024, with a compound annual growth rate (CAGR) of 4.7% from 2020 to 2024 [6]. - The special medical food market is expected to grow even faster, reaching 23 billion RMB by 2024, with a CAGR of 23.1% during the same period [6]. Competitive Landscape - Yipin Nutrition ranks second in the domestic market for infant formula goat milk powder, with a market share of 14.0% [8]. - The company has successfully narrowed the gap with international giants like Abbott and Nestlé, achieving quality standards comparable to those in Europe [8]. Future Opportunities - New entrants in the low-allergen dairy and special medical food sectors can explore three main growth areas: functional formula powders, high-end adult nutrition powders, and cross-border market expansion [9][10]. - The demand for functional formula powders is shifting towards "precision nutrition," with products targeting specific needs such as allergy and nutritional supplementation [9]. - The adult high-end nutrition powder market is projected to reach 820 million RMB by 2024, with a growth rate exceeding 28% [9].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 在中国奶粉市场逐渐步入细分竞争的时代，羊奶粉与特殊医学用途配方食品成为资本关注的新焦点。近 期，继圣桐特医之后，宜品营养科技（青岛）集团股份有限公司（以下简称"宜品营养"）正式向港交所 递交招股书，拟在香港主板上市。作为国内羊奶粉行业第二大企业，宜品营养的上市动向引发市场广泛 关注。然而，在其看似亮眼的业绩背后，却隐藏着盈利波动、产能利用不足、库存高企等多重风险。 销售费用增速高于营收增速 今年上半年营收、净利双降 数据显示，宜品营养在过去三年中营业收入呈现稳步增长态势。2022年至2024年，公司营收分别为 14.02亿元、16.14亿元和17.62亿元。尽管收入规模持续扩大，但其净利润却出现明显波动。 高毛利却未能转化为稳定盈利的主要原因包括生产成本上升、销售及分销费用增加、行政开支扩大以及 资产减值损失等。 其中，2022年-2024年公司销售费用分别为2.4亿元、3.71亿元、4.32亿元，23年、24年销售费用同比增 长率分别达54.58%、16.44%，同期公司营收同比增速分别为15.17%、9.17%，增速显著低于销售费用 ...

经济观察网 有着"中国第二大羊奶粉企业"之称的宜品营养科技（青岛）集团股份有限公司（以下简 称"宜品营养"）正式向港交所主板递交上市申请。 在中国乳制品行业细分赛道竞争白热化的背景下， 宜品营养试图通过IPO进行国际扩张。然而，就在上市前夕，公司却交出了一份承压的中期成绩单：受 羊奶粉市场增长乏力影响，2025年上半年， 宜品营养营收与净利润双双下滑，经营活动产生的现金流 量净额同比骤降超60%。 穿透招股书，宜品营养"三费"均呈增长态势，其中销售费用更是节节攀升。 与之形成鲜明对比的是，本就投入极低的研发费用，却在进一步缩减。且在IPO前，公司频频大额分 红， 净利骤降超4成，库存周转承压 招股书显示，2022-2024年，宜品营养营收实现了稳步增长，分别 录得14.02亿元、16.14亿元和17.62亿元；净利润有所波动，分别为2.27亿元、1.68亿元、1.72亿元。 今 年上半年，宜品营养营收、净利双降，实现营收8.06亿元， 同比减少10.34%；实现净利润5668.8万元， 同比暴跌42.57%。 从产品来看，宜品营养的产品集中度极高。 2022-2024年，婴幼儿配方羊奶粉收入分 别为7.72亿 ...

Core Viewpoint - Yipin Group, the second-largest goat milk powder brand in China, has officially submitted its IPO application to the Hong Kong Stock Exchange, drawing attention to the company's vice president, Yu Haixia [1][3]. Financial Performance - Yipin Group's revenue for 2022, 2023, and 2024 is projected to be 1.4 billion yuan, 1.61 billion yuan, and 1.76 billion yuan respectively, with net profits of 227 million yuan, 168 million yuan, and 172 million yuan [3][4]. - In the first half of this year, Yipin Group reported revenue of 806 million yuan, a decrease of 10.34% compared to 899 million yuan in the same period last year, with profits dropping by 42.42% from 98.7 million yuan to 56.7 million yuan [3][5]. Product Performance - The core product, infant formula goat milk powder, accounted for over 50% of Yipin Group's revenue from 2022 to 2024, with revenues of 772 million yuan, 926 million yuan, and 1.03 billion yuan respectively, indicating steady growth [4]. - However, in the first half of this year, revenue from infant formula goat milk powder was 448 million yuan, down 18.5% from 550 million yuan in the same period last year [5]. Market Position - Yipin Group holds a 14.0% market share in the domestic goat milk powder market, ranking second, only behind Ausnutria's Kabrita [4]. Management Background - Yu Haixia, the vice president of Yipin Group, has a diverse work history, including roles in marketing and management across various companies, which contributes to her extensive management experience [6][7][8].

据董事长牟善波介绍，健康宝宝可选用其牛奶粉或羊奶粉，轻度过敏宝宝有宜品羊奶粉提供支持，而针 对超敏及重度过敏宝宝，则可提供相应的特医食品解决方案。 婴幼儿配方羊奶粉、特医食品作为两大核心业务板块，是宜品乳业的领先优势所在，2025年上半年分别 贡献总营收的56%、16%。 以2024年35亿元零售额计，宜品乳业以14%的市场份额在中国羊奶粉市场位居第二，仅次于伊利旗下的 澳优乳业。 在婴儿特医食品市场中，宜品乳业以4.5%的市占率同样排名本土品牌第二。 然而公司仍难以回避奶粉行业整体增长放缓所带来的压力。 母婴行业IPO阵营迎来一名重要参与者。 近日，宜品营养科技（青岛）集团股份有限公司（简称"宜品乳业"）正式向港交所递交主板上市申请。 宜品乳业的产品体系围绕过敏体质婴幼儿的营养需求展开。 2024年，宜品乳业实现营收17.6亿元，收入增幅由去年同期15%放缓至9.2%；剔除生物资产未变现公允 价值变动影响后，利润由1.81亿元降至1.73亿元。 2025年上半年，营收同比下滑10%至8.1亿元，其中婴幼儿配方羊奶粉收入同比下降近两成；净利润下 跌超过四成。 支柱业务羊奶粉增长遭遇瓶颈，特医食品等新业务尚处发 ...

羊奶粉巨头宜品集团正式冲刺IPO。 近日，宜品营养科技(青岛)集团股份有限公司(下称"宜品集团")向港交所递交上市申请，计划在主板挂 牌上市，海通国际与中信建投（601066）国际担任本次上市的联席保荐人。 宜品集团自称是"中国领先营养科技集团"，专注于羊奶粉及特殊医学用途配方食品领域。根据弗若斯特 沙利文报告的数据，2024年其在中国羊奶粉市场排名第二，市场份额为14.0%。 但长江商报记者注意到，这个"行业老二"IPO之路隐忧重重。财务数据显示，2025年上半年公司营收、 净利分别同比下滑10.36%、42.57%；净利率从2022年的16.2%持续降至7.0%。 招股书显示，2022年—2025年上半年，宜品集团销售及分销费用逐年攀升，分别达到2.4亿元、3.71亿 元、4.32亿元、2.33亿元，占总营收比重分别为17.1%、23%、24.5%、28.91%，这也从侧面反映了奶粉 市场竞争之激烈。 公司"重营销轻研发"特征显著。2025年上半年，其销售及分销费用占比升至28.91%，研发费用率不足 0.5%。 存货风险也值得关注。2025年上半年，宜品集团的存货规模进一步增长至8.02亿元，库存周转天 ...

Core Viewpoint - The company Yipin Nutrition is preparing for an IPO in Hong Kong, focusing on the production of goat milk powder and specialized medical formula foods, with projected revenue exceeding 1.7 billion RMB in 2024 and a gross margin of approximately 50% [1][2]. Company Overview - Yipin Nutrition, headquartered in Qingdao, Shandong, has a history dating back to 1956 and began producing its own brand "Ainiko" in 2011. The company launched its first goat milk powder product in 2016 and has since expanded its operations internationally [2]. - The company specializes in goat milk powder and specialized medical formula foods, catering to consumers of all ages, particularly those with allergies or lactose intolerance [2]. Financial Performance - Yipin Nutrition has shown a revenue growth trend, with revenues of approximately 1.4 billion RMB in 2022, 1.6 billion RMB in 2023, and projected 1.76 billion RMB in 2024. However, net profits have fluctuated, with 2022 net profit at 227 million RMB, dropping to 168 million RMB in 2023 [12][13]. - The company has a significant reliance on infant formula goat milk powder, which contributed 58.6% of its revenue in 2024 [6]. Dividend Policy - Prior to its IPO, Yipin Nutrition has distributed dividends multiple times, including 211 million RMB in February 2023, which exceeded its net profit for that period [4]. Market Position - Yipin Nutrition is the second-largest goat milk powder company in China, holding a market share of 14%, following Ausnutria [15]. The goat milk powder retail market in China has been growing, with a compound annual growth rate of 4.7% from 2020 to 2024 [14]. Competitive Landscape - The company faces competition from major players like Yili and Ausnutria, as well as challenges from the increasing popularity of imported products due to cross-border e-commerce [16]. The goat milk powder market is becoming increasingly competitive, influenced by factors such as declining birth rates and heightened consumer expectations for food safety [16].